Ondansetron doesn’t forestall bodily dependence in sufferers taking opioid medicines chronically for ache management.
Drug Alcohol Rely. 2017 Aug 14;183:176-183
Authors: Chu LF, Rico T, Cornell E, Obasi H, Encisco EM, Vertelney H, Gamble JG, Crawford CW, Solar J, Clemenson A, Erlendson MJ, Okada R, Carroll I, Clark JD
OBJECTIVES: On this research, we investigated the co-administration of ondansetron with morphine, and whether or not it might forestall the event of bodily dependence in sufferers taking opioids for the therapy of power ache.
METHODS: A complete of 48 power again ache sufferers (N?=?48) participated on this double-blinded, placebo-controlled, randomized research. Sufferers had been titrated onto sustained-release oral morphine and randomized to take eight?mg ondansetron or placebo 3 times each day concurrently with morphine in the course of the 30-day titration. Following titration, sufferers underwent Naloxone induced opioid withdrawal. Opioid withdrawal indicators and signs had been then assessed by a blinded analysis assistant (goal opioid withdrawal rating: OOWS) and by the analysis participant (subjective opioid withdrawal rating: SOWS).
RESULTS: We noticed clinically vital indicators of naloxone-precipitated opioid withdrawal in all individuals (?OOWS?=?four.three?±?2.four, p?<?zero.0001; ?SOWS?=?14.1?±?11.7, p?<?zero.0001), nevertheless no vital variations in withdrawal scores had been detected between therapy teams.
CONCLUSION: We hypothesized that ondansetron would forestall the event of bodily dependence in human topics when co-administered with opioids, however discovered no distinction in naloxone-precipitated opioid withdrawal scores between ondansetron and placebo therapy teams. These outcomes counsel that additional research are wanted to find out if 5HT3 receptor antagonists are helpful in stopping opioid bodily dependence.
PMID: 29278818 [PubMed – as supplied by publisher]